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Abstract Malaria, the disease caused by Plasmodium infec-
tion, is endemic to poverty in so-called underdeveloped
countries. Plasmodium falciparum, the main infectious
Plasmodium species in sub-Saharan countries, can trigger
the development of severe malaria, including cerebral
malaria, a neurological syndrome that claims the lives of
more than one million children (<5 years old) per year.
Attempts to eradicate Plasmodium infection, and in partic-
ular its lethal outcomes, have so far been unsuccessful.
Using well-established rodent models of malaria infection,
we found that survival of a Plasmodium-infected host is
strictly dependent on the host’s ability to up-regulate the
expression of heme oxygenase-1 (HO-1 encoded by the gene
Hmox1). HO-1 is a stress-responsive enzyme that catabolizes
free heme into biliverdin, via a reaction that releases Fe and
generates the gas carbon monoxide (CO). Generation of CO
through heme catabolism by HO-1 prevents the onset of
cerebral malaria. The protective effect of CO is mediated via
its binding to cell-free hemoglobin (Hb) released from
infected red blood cells during the blood stage of Plasmo-
dium infection. Binding of CO to cell-free Hb prevents heme
release and thus generation of free heme, which we found to
play a central role in the pathogenesis of cerebral malaria.
We will address hereby how defense mechanisms that
prevent the deleterious effects of free heme, including the
expression of HO-1, impact on the pathologic outcome of
Plasmodium infection and how these may be used therapeu-
tically to suppress its lethal outcomes.
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Severe malaria
Malaria affects an estimated 300–500 million new individ-
uals every year [1]. The life cycle of Plasmodium, the
causative agent of malaria, involves initially a clinically
silent “liver stage” (reviewed in [2, 3]) and thereafter a
“blood stage” (reviewed in [3, 4]) associated with the
appearance of overt clinical signs including prostration,
respiratory distress, pulmonary edema, convulsions, circu-
latory collapse, abnormal bleeding, jaundice (reflective of
hepatic failure), hemoglobinuria, severe anemia, and/or
impaired consciousness [1] (reviewed in [5, 6]). Severe
malaria is defined by the occurrence of one or more of these
clinical signs in individuals with no apparent cause of
disease other than Plasmodium infection. Cerebral malaria,
probably the most lethal form of severe malaria, is defined
clinically by the development of coma, occurring at least 1h
after termination of a seizure or correction of hypoglyce-
mia, in individuals where asexual forms of Plasmodium are
detected and in which other causes of encephalopathy have
been excluded (reviewed in [5]). Lethal forms of severe
malaria, including cerebral malaria, are in most cases
associated with impaired consciousness, respiratory distress
and severe anemia (reviewed in [5, 7]), accounting for the
death of more than one million children (<5 years old) per
year mainly in sub-Saharan Africa [1].
Pathogenesis of severe malaria
Epidemiologically, lethality associated with Plasmodium
infection is a rare event, i.e., less than 1–2% of afflicted
individuals succumb to infection [1]. This suggests that
Plasmodium co-evolved with humans to reach an evolu-
tionary “trade-off” in which its life cycle does not
compromise that of its host. The cellular and molecular
mechanism(s) insuring host viability are thought to rely
almost exclusively on its ability to mount an effective
immune response against Plasmodium. Over the years,
however, it has become apparent that this immune response
can contribute in a critical manner to the pathogenesis of
severe malaria. Based on its resemblance to the human
disease, Plasmodium infection in mice has been widely
used to identify cellular and molecular mechanisms
underlying the pathogenesis of severe and/or cerebral
malaria [8, 9] (reviewed in [3]). The validity of this
approach is supported by the finding that some of the key
genes involved in the pathogenesis of severe malaria in
mice, e.g., tumor necrosis factor (Tnf), lymphotoxin (Lt),
intracellular adhesion molecule-1 (Icam-1), and nitric oxide
synthases (Nos), are also involved in the pathogenesis of
severe malaria in humans (reviewed in [3]).
Plasmodium infection elicits in its host an innate immune
response that is critically involved in the pathogenesis of
severe malaria. As for other infectious agents, Plasmodium
expresses pathogen-associated molecular patterns (PAMP)
that can be recognized by host germline-encoded pattern
recognition receptors (PRR; reviewed in [10]). These signal
in innate immune cells, such as monocyte/macrophages
(Mø), to elicit a potent pro-inflammatory response. Glyco-
sylphosphatidylinositol, a glycolipid expressed at the surface
of Plasmodium, is recognized via PRR belonging to the
Toll-like receptor (TLR) family, i.e., TLR2/TLR1 or TLR2/
TLR6 complexes and to a lesser extent TLR4 [11].
Hemozoin, a crystal derived from heme and generated by
Plasmodium (see “The HO system”), can also be recognized
by TLR9 [12, 13].
The contribution of these PRR to the pathogenesis of
severe malaria is suggested by the following set of observa-
tions. Polymorphisms in human TLR4 (Asp299Gly/
Thr399Ile) and TLR9 (T-1486C) are associated with suscep-
tibility to severe malaria in children [14] and with the
outcome of Plasmodium infection during pregnancy [15],
respectively. There is also a polymorphism (Ser180Leu) in
Mal/TIRAP (an adaptor molecule required for TLR2 and
TLR4 signaling) associated with susceptibility to severe
malaria [16]. The involvement of these PRR in the
pathogenesis of severe malaria in rodents remains contro-
versial, with some reports suggesting an active role [13]
while others not [17, 18].
The contribution of host adaptive immunity to the
pathogenesis of severe malaria is well illustrated in
rodent models of Plasmodium infection (reviewed in
[3, 19]). Once primed by dendritic cells, presumably
in the spleen, (TH) cells foster the co-activation of CD8
+
T helper cells. It has been suggested that activated CD8+
T cells can target brain microvascular endothelial cells,
triggering endothelial cell activation and ultimately
granzyme- and perforin-dependent programmed cell
death, promoting the onset of cerebral malaria (reviewed
in [3, 19]).
The evolutionary “trade-off” allowing Plasmodium and
its host to coexist might require an additional mechanism of
host defense that does not necessarily involve the host
immune response targeting Plasmodium [20]. We reasoned
that such a mechanism might operate in a manner that
limits the deleterious effects of red blood cell (RBC) lysis, a
phenomenon inherent to Plasmodium infection. Hemolysis
is associated with release of an estimated 20% to 40% of
the initial pool of RBC hemoglobin (Hb) into the
circulation (reviewed in [21]). Cell-free Hb can release its
heme prosthetic groups, which, as discussed in the next
section, is a highly deleterious event that can promote the
onset of severe malaria (Fig. 1).
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Deleterious effects of free heme
Erythrocytic forms of Plasmodium are in intimate contact
with Hb, degrading approximately 60% to 80% of the total
RBC Hb content to use it as a vital source of amino acids
(reviewed in [21]). Hb degradation, however, generates free
heme and reactive oxygen species (ROS), the combination
of which is highly deleterious to erythrocytic schizonts [22]
as well as to the infected host.
At concentrations below 5 mM, such as outside RBC,
cell-free Hb tetramers dissociate spontaneously into dimers
(reviewed in [23]; Fig. 1). In the presence of ROS or
reactive nitrogen species (RNS), cell-free Hb dimers are
readily oxidized into methemoglobin (metHb), releasing its
heme prosthetic groups [24–26] (reviewed in [23, 27];
Fig. 1). Free heme can be highly cytotoxic to endothelial
cells [24–26], a pathologic event that exposes the pro-
thrombotic sub-endothelial matrix to the coagulation cas-
Fig. 1 Defense mechanisms against the free heme generated via Hb
oxidation. When released from infected RBC, ferrous HbFe2+ (α2β2)
tetramers disaggregate spontaneously into Hb (αβ) dimers. In the
presence of ROS (or RNS), cell-free Hb (αβ) dimers are readily
oxidized into ferric HbFe3+ (αβ), i.e., metHb. In this process, ferryl
HbFe4+ (αβ), a short-lived intermediate is also generated [93], which
can result in a potent pro-inflammatory response (Gabriela Silva,
unpublished observations). Under homeostatic conditions, ferric
HbFe3+ (αβ) is scavenged by haptoglobin (Hp). The very high
affinity of Hp towards Hb (>1010 mol−1 in humans) is sustained by
two Hp-binding sites in the Hb β chain, i.e., β11–25 and β131–146 and
one in the α chain, i.e., α121–l27 [94]. Binding of Hp to Hb also
stabilizes heme, inhibiting its release [95]. During Plasmodium
infection, plasma Hp is depleted, allowing ferric HbFe3+ (αβ) to
release heme. Plasma free heme can be scavenged by hemopexin
(Hpx), a plasma protein folded into two homologous β-propeller
domains joined by a linker and binding a single heme molecule via
His213 and His266 with the highest affinity (Kd<10
−12 M in humans) of
any other protein described so far [96]. Additional non-covalent
interactions between hydrophobic residues of Hpx and the porphyrin
ring and propionate groups of heme act as electrostatic anchors that
contribute to heme binding and to coordinate its Fe3+ as well. Once
the scavenging capacity of Hpx is exhausted, plasma free heme can be
scavenged by albumin, which has two tyrosine residues, i.e., Tyr138
and Tyr161 that provide a D-shaped cavity limited by p–p stacking
interaction with the porphyrin ring of heme with an affinity that is
however, 104 times lower to that of Hpx (Kd=10
–8 M in humans) [97].
In addition, this 3D structure supplies a donor oxygen (from Tyr161) to
the Fe atom of heme, maintaining it in its reduced state, i.e., Fe2+. The
interaction of heme with human albumin is further stabilized by two
salt bridges, provided by the albumin Arg114 and Lys190 residues
(reviewed in [98]). When the scavenging capacity of Hp, Hpx and
albumin are exhausted, there is yet an ultimate defense mechanism to
avoid free heme accumulation in plasma, i.e., heme catabolism by
HO-1. If this is still not sufficient to clear all the free heme generated
from Hb oxidation, a pathologic positive-forward feedback loop is
formed in which free heme promotes the generation of ROS that
sustain the oxidation of cell-free Hb, with further generation and
accumulation of free heme in plasma, ultimately leading to irreversible
oxidative injury
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cade, leading to formation of more or less extensive
microvascular thrombi with concomitant vaso-occlusion
and tissue ischemia.
The underlying cause of free heme cytotoxicity involves
most probably its highly hydrophobic nature, which allows
the Fe contained within its protoporphyrin IX ring to enter
and cross cell membranes as well as other lipid structures
[25]. The Fe contained within the protoporphyrin IX ring
can act as a potent pro-oxidant, donating electrons that
foster the generation of ROS and/or RNS via the Fenton
chemistry. This can also occur when Fe is released from the
protoporphyrin IX ring of heme, either through non-
enzymatic oxidative degradation or enzymatic cleavage,
catalyzed by heme oxygenases (HO) [28] (see “Expression
of HO-1 modulates the onset of severe malaria”). There is
also the possibility that as for other hydrophobic molecules
[29], endothelial cells might express “heme receptors” that
could mediate its cytotoxic effects [30].
Additional mechanisms via which free heme can be
deleterious to endothelial cells include its ability to promote
oxidative modification of low-density lipoproteins (LDL)
[24, 25]. Heme-assisted LDL oxidation, involving sponta-
neous insertion of heme into LDL particles coupled with
oxidative interactions between LDL and heme, can lead to
oxidative modifications in LDL that are highly cytotoxic to
endothelial cells [24].
Free heme can act as a polymorphonuclear (PMN) cell
chemoatractant [31], sustaining PMN cell activation [32]
and survival [33], thus fostering the generation of ROS that
can synergize with free heme to promote further endothelial
cell cytotoxicity. As activation of PMN leukocytes by free
heme is blocked by pertussis toxin, these cells might
recognize free heme specifically via G-protein-coupled
receptors [31].
In addition to targeting endothelial cells, free heme can
also exert deleterious effects in other cell types. We have
recently found that free heme sensitizes non-hematopoietic
cells to undergo TNF-mediated programmed cell death
(Seixas et al., manuscript submitted for publication).
Probably explaining the critical involvement of TNF to
the onset of severe malaria [34].
Defense mechanisms against the deleterious effects
of free heme
Plasmodium evolved a series of defense mechanisms
against the deleterious effects of free heme, such as its
polymerization into hemozoin, an inert crystal in which the
Fe atoms in the protoporphyrin IX ring of heme can no
longer act as pro-oxidant catalysts (reviewed in [21]). The
importance of this defense mechanism is revealed by the
potent therapeutic effects of anti-malarial drugs that inhibit
hemozoin formation [35]. While this strategy, i.e., hemo-
zoin formation, allows erythrocytic forms of Plasmodium to
replicate efficiently within the confined space of a RBC, it
does generate a major caveat, namely that Plasmodium
replication will unavoidably lead to hemolysis and Hb
release into the circulation (reviewed in [21]).
Given the highly deleterious effects of free heme to the
infected host, there might be a reason why accumulation of
cell-free Hb has been maintained throughout evolution. One
possible explanation is that cell-free Hb can act as a host
innate defense mechanism [36]. This notion is supported by
the recent observation that cell-free Hb can recognize
molecular patterns expressed specifically by microbial
organisms, an effect that when coupled to heme-assisted
ROS production, can lead to the clearance of blood-borne
microbial pathogens [36]. Whether this innate defense
mechanism can target Plasmodium remains to be tested
experimentally.
Despite its putative beneficial effects, several defense
mechanisms have evolved to cope with the cytotoxicity of
cell-free Hb. Under homeostatic conditions, cell-free Hb
can be readily scavenged by haptoglobin (Hp), a tetrameric
(α2β2) plasma protein (human; P00738). Hb/Hp complexes
are recognized and internalized via the Hp receptor
(CD163) expressed by monocyte/macrophages (Mø) in the
red pulp of the spleen [37]. This allows for heme
degradation via the HO system (“Defense mechanisms
against the deleterious effects of free heme”; Figs. 2 and 3).
Contrary to the β chain of Hp (β, ~40 kDa) its α chain has
two allelic variants, i.e., Hp1 (α1, ∼8.86 kDa) and Hp2 (α2,
∼17.3 kDa) that give rise to three possible Hp phenotypes,
i.e., Hp1.1, Hp1.2, and Hp2.2 [38]. These have graded
affinities for cell-free Hb, i.e., Hp1.1>Hp1.2>Hp2.2, as
well as for CD163, i.e., Hp2.2>Hp1.2>Hp1.1 [37]. Indi-
viduals expressing the Hp2.2 phenotype are less likely to
develop severe malaria [39], suggesting the existence of a
stringent process of natural selection targeting this Hp allele
in endemic areas of Plasmodium infection.
Under hemolytic conditions, such as during Plasmodium
infection, circulating Hp can be depleted, leading to
accumulation of cell-free Hb in plasma. In keeping with
this notion, 20–40% of children infected by Plasmodium
falciparum in sub-Saharan countries present undetectable
levels of plasma Hp [40]. Presumably, for this reason, cell-
free metHb does accumulate in the plasma of individuals
suffering from severe malaria [41, 42], which should lead to
the prompt release of its heme prosthetic groups (Fig. 1).
When this occurs, there are additional mechanisms that can
prevent the accumulation of free heme in plasma. One of
these relies on hemopexin (Hpx), a monomeric plasma
protein (~63 kDa; human; P02790; Figs. 1 and 2). Under
homeostasis, Hpx can scavenge most of the free heme that
accumulates in plasma, forming Hpx/heme complexes.
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These are recognized by the Hpx receptor (CD91)
expressed in hepatocytes, Mø, fibroblasts, adipocytes,
neurons, and trophoblasts [43] (Fig. 2). Internalization of
these complexes via CD91-assisted endocytosis allows for
heme degradation via the HO system [43] (Figs. 2 and 3).
Once the scavenging capacity of plasma Hpx is exhausted,
free heme can still be scavenged by plasma albumin
(~66 kDa; human; P02768; Fig. 1). Whether heme/albumin
complexes are recognized by specific receptors allowing for
heme degradation via the HO system has not been
established.
We have recently described that the onset of severe
malaria in mice is associated with the accumulation of high
concentrations of free heme in plasma [8], suggesting that
the capacity of plasma Hp, Hpx, and albumin to prevent
free heme accumulation is exhausted during the onset of
severe malaria (reviewed in [23, 27]). However, there is yet
an ultimate defense mechanism to avoid the deleterious
effects of free heme, namely its catabolism by the cellular
HO system (Fig. 3).
The HO system
Heme oxygenases (EC1.14.99.3) are encoded by three
distinct genes, i.e., HMOX1 (human; P09601), HMOX2
(human; P30519), and Hmox3 (rat; O70453). HMOX1 and
HMOX2 encode two distinct proteins, i.e., HO-1 (32 kDa)
and HO-2 (37 kDa), respectively, while Hmox3 is most
probably a pseudogene. Under oxidative stress, HO-1
Fig. 2 Defense mechanisms
against free heme are coupled
to heme degradation by HO-1.
When cell-free ferric HbFe3+
(αβ), i.e., metHb, accumulates
in plasma, it can be scavenged
by circulating haptoglobin (Hp)
to be delivered to the Hp recep-
tor (CD163) expressed by Mø in
the red pulp of the spleen. This
allows for sheltering of the heme
prosthetic groups of HbFe3+
(αβ) as well as for catabolism of
the heme groups by HO-1, con-
stitutively expressed by CD163+
Mø. If released from ferric
HbFe3+ (αβ), free heme can be
scavenged by very high affinity
binding to hemopexin (Hpx) and
delivered to liver hepatocytes
and Mø expressing the Hpx
receptor (CD91). Expression of
HO-1 in liver hepatocytes and
Mø ensures heme catabolism.
During the onset of severe ma-
laria, the pool of plasma Hp and
Hpx is exhausted, and free heme
accumulates in plasma. Free
heme can cross cell membranes,
e.g., in endothelial cells, where
it synergizes with oxidants to
induce the expression of HO-1
by which it is catabolyzed.
Pathology will only develop
when all these defense systems
are overwhelmed
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expression is induced ubiquitously, while the expression of
HO-2 remains unchanged [8]. Both HO isoforms can cut
the protoporphyrin IX ring of free heme, releasing Fe from
its inner core and generating carbon monoxide (CO; Fig. 3).
The remaining protoporphyrin structure gives rise to
biliverdin, which can be converted by biliverdin reductase
into bilirubin, a potent antioxidant [44] (Fig. 3). Biliverdin
reductase can also trigger signal transduction and probably
mediate in this manner some of the biologic effects
attributed to biliverdin (reviewed in [45]).
Heme catabolism by the HO system rids cells of a
membrane-permeant Fe, i.e., heme. However, the Fe
released via heme catabolism represents a potential hazard,
unless sequestered by ferritin [46], which acts as a vital
antioxidant in various experimental models [46–48]. Ferri-
tin is a multimeric (24-subunit) protein (H chain, 21 kDa, L
chain, 20.7 kDa) with high Fe storing capacity (4,500 mol
of Fe per mole of ferritin). The proportion of H and L
subunits in the ferritin shell depends on the Fe status of the
cell (reviewed in [49]). The protective effects of ferritin are
attributable in large measure to the ferroxidase activity of
the H chain subunit [50], which catalyzes the oxidation of
(ferrous) Fe2+ formed by superoxide or endogenous
reductants into (ferric) Fe3+. This process, i.e., Fe nucle-
ation, facilitates Fe insertion into multimeric ferritin
structures, allowing for the functional storage and inactiva-
tion of labile (ferrous) Fe2+ that is otherwise capable of
fueling the production of toxic hydroxyl radicals (OH.) via
the Fenton chemistry.
It is now well established that induction of HO-1
expression plays a pivotal role in the resolution of
inflammatory conditions (reviewed in [51]). Malaria seems
to provide yet another situation where the potent protective
effects of HO-1 are exerted [8].
Expression of HO-1 modulates the onset of severe
malaria
Plasmodium infection, in both mice and humans, is
associated with the induction of high levels of HO-1
expression that is neither restricted to a specific cell type
nor to a specific organ [8, 52–54]. We found that mouse
strains that express high levels of HO-1 in response to
Plasmodium infection do not succumb to severe and/or
cerebral malaria, while those that express low levels of
HO-1 do so [8] (Seixas et al., manuscript submitted for
publication). Perhaps more importantly, deletion of the
Hmox1 locus by homologous recombination is sufficient
per se to promote the onset of severe and/or cerebral
malaria [8] (Seixas et al., manuscript submitted for
publication). These observations reveal that induction of
HO-1 expression is part of a protective mechanism that
suppresses the onset of severe and/or cerebral malaria in
mice.
Contrary to HO-1, the expression of HO-2 is not induced
in response to Plasmodium infection in mice [8], which
would suggest that HO-2 is not critically involved in
modulating the pathogenesis of severe and/or cerebral
malaria. However, as the outcome of Plasmodium infection
in Hmox2-deficient mice has not been reported, we cannot
at this point exclude the possibility that HO-2 might
Fig. 3 The heme oxygenase
system. HO-1 catabolizes free
heme into biliverdin. Initially,
free heme intercalates in the
heme-binding pocket of apo
HO-1, which cleaves the proto-
porphyrin IX ring using one O2
molecule and electrons donated
by NAD(P)H/CytP450 reduc-
tase via a reaction releasing Fe2+
(yellow circle) from its inner
core and generating carbon
monoxide (CO; gray and red
circle). Biliverdin, the protopor-
phyrin structure released from
the heme pocket of HO-1, can
be converted into bilirubin by
biliverdin reductase (BVR),
which uses NAD(P)H as elec-
tron donors. All three end prod-
ucts of this reaction, i.e., Fe,
CO, and bilirubin, can dampen
the deleterious effects of in-
flammatory reactions
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modulate the pathogenesis of severe and/or cerebral
malaria.
Probably critical to our understanding of the mechanism
of action of HO-1 is the observation that its protective
effects do not correlate with modulation of “parasite
burden”, i.e., percentage of infected RBC [8]. This suggests
that HO-1 can prevent the lethal outcome of Plasmodium
infection without interfering with the host immune response
controlling parasite burden [8], a general host defense
mechanism against infection referred to as “tolerance” [20].
Based on the extremely well-conserved nature of this
enzymatic system among mice and humans, it is possible
that HO-1 expression might also be protective against the
onset of severe and/or cerebral malaria in Plasmodium-
infected children.
If one assumes that HO-1 might play a central role in
modulating the pathogenesis of severe malaria in humans,
then the prediction would be that spontaneous mutations
selected through evolution based on their protective effect
against severe malaria might act via HO-1. Sickle cell trait,
caused by a single point mutation in one of the Hb β-globin
chain locus, is probably the best-characterized of such
mutations. Sickle cell trait can be associated with the
occurrence of mild hemolysis and heme release into the
circulation. When exposed chronically to low levels of free
heme, cells up-regulate the expression of HO-1 [25, 26,
46], probably explaining why individuals carrying this
mutation can have high level of HO-1 expression [55]. It is
therefore tempting to speculate that up-regulation of HO-1
might contribute to the protective effect of this hematolog-
ical condition against the onset of severe malaria. It is also
possible that a similar protective mechanism, involving
HO-1, could contribute to explain how other hemolytic
disorders such as α- and β-thalassemia or glucose 6-
phosphate dehydrogenase deficiency also afford protection
against severe malaria. However, this remains to be tested
experimentally.
Spontaneous disruption of the HMOX1 locus in humans
is lethal [56], excluding the possibility of establishing a
linear functional link between HO-1 expression and the
outcome of Plasmodium infection. However, there is a (GT)
n microsatellite polymorphism in the human HMOX1
promoter that regulates in a quantitative manner its
response to many stimuli (reviewed in [57]). Individuals
with fewer (GT)n repeats have a high HO-1 inducibility,
while those with higher (GT)n repeats have a lower
response (reviewed in [57]). There are now multiple studies
demonstrating that individuals responding more strongly,
i.e., fewer (GT)n repeats, are also less likely to develop a
series of pathologies (reviewed in [57]). However, in the
case of Plasmodium infection, this relationship does not
seem to be straightforward. In a recent study, children that
succumbed to cerebral malaria were shown to carry more
frequently the homozygous short (GT)n repeats (n < 28;
high HO-1 inducibility) than those that do not develop this
syndrome [58]. As a cautionary note, however, this study
was performed in a very limited sample size, and no
correlation between the (GT)n polymorphism and HO-1
expression was assessed in the context of Plasmodium
infection [58]. Nevertheless, assuming that in Plasmodium-
infected children the homozygous short (GT)n repeats
afford high level of HO-1 expression but no protection
against the onset of cerebral malaria, this might be
explained by the following set of observations in mice.
Expression of HO-1 is significantly induced during the
hepatic stages of Plasmodium infection [59]. More impor-
tantly, when Hmox1 is deleted by homologous recombina-
tion, generation of liver merozoites is reduced by ~70–80%
[59]. This would suggest that a viable interaction of
Plasmodium with its host is strictly dependent on the
induction of HO-1 expression during both liver and blood
stages of infection. Namely, HO-1 expression might favor
initially the generation of liver merozoites and their
progression into the blood, while expression of HO-1
thereafter might prevent the onset of severe malaria. While
this interpretation does not take away the critical role of
HO-1 in suppressing the pathogenesis of severe malaria, it
suggests that Plasmodium interaction with its human host
might have evolved in a way that subverts the HO-1 system
to promote both Plasmodium and host survival.
CO and expression of heavy chain ferritin (FtH) prevent
the onset of severe malaria
Congruous with previous observations in other experimen-
tal models of disease [60–63], we found that CO can
prevent the development of cerebral malaria in mice [8].
Briefly, under experimental conditions in which more then
95% of Plasmodium-infected mice develop cerebral malaria,
CO inhalation (250 ppm) at different times after infection
reduces the incidence of cerebral malaria to less than 5% [8].
As for HO-1, CO does not modulate parasite burden,
suggesting that it affords host tolerance against Plasmodium
infection [20]. That is, CO limits disease severity, i.e., death,
associated with a given parasite burden.
The finding that CO can prevent the onset of cerebral
malaria in mice could have important implications for the
treatment of this disease in humans, as the protective effect
of CO is achieved when applied as late as 4–5 days post-
infection at a dosage as low as 250 ppm [8]. This suggests
that CO might be used therapeutically, after infection, to
prevent the onset of cerebral malaria in humans.
We have also tested whether other end products of heme
catabolism by HO-1 exert protective effects. Biliverdin,
which we have shown to elicit potent protective effects in
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other experimental models of disease [64], failed to prevent
the development of cerebral malaria in mice [8]. This
suggests that biliverdin/bilirubin is probably not the main
effector mechanism via which HO-1 affords protection
against severe and/or cerebral malaria. However, as a
cautionary note, failure of biliverdin to exert protective
effects may be due to its inability to cross the blood brain
barrier (BBB).
Finally, we have recently found that expression of FtH in
non-hematopoietic cells suppresses the cytotoxic effects of
free heme and prevents the lethal outcome of severe malaria
in mice (Seixas et al., manuscript submitted for publica-
tion). This salutary effect, which requires FtH ferroxidase
activity, acts independently of host immunity against
Plasmodium, suggesting that in a similar manner to CO,
expression of FtH can limit disease severity and prevent the
lethal outcome of severe malaria under a given parasite
burden [20].
Are the protective effects of CO mediated via signal
transduction?
Understanding further the mechanism(s) of action of CO
might improve the possibility of using this gaseous
molecule for therapeutic purposes in humans. There are
now several studies suggesting that CO exerts anti-
inflammatory [61], cytoprotective [65], and anti- prolif-
erative effects [62] that act in a concerted way to prevent
the deleterious effects associated with the development
of many pathologic conditions, such as hyperoxic lung
injury, rejection of transplanted organs, ischemia and
reperfusion injury, severe sepsis or arteriosclerosis,
among others (reviewed in [51]). These studies also
suggested that CO acts as a signal transduction molecule
to down-modulate inflammation and afford cytoprotec-
tion as well as to prevent unfettered cell proliferation
(reviewed in [51]). These effects should contribute to the
ability of CO to prevent the onset of severe and/or
cerebral malaria.
CO can react with reduced divalent metals and in
particular with Fe2+ contained within the heme groups of
hemoproteins (reviewed in [66]). The relative affinity of
CO for different heme prosthetic groups is dictated not only
by their Fe “redox status” (Fe2+ versus Fe3+) but also by the
amino acid sequence in the “heme-binding motifs” of these
hemoproteins. This was demonstrated originally for Hb and
later for guanylate cyclase, an enzyme that generates the
signal transduction molecule cyclic GMP (cGMP) [67]
(reviewed for Hb in [68]). In the case of guanylate cyclase,
the amino acid sequence of its heme-binding motifs impose
that CO binds to heme in a manner that is distinct from that
of other biologically active gases such as nitric oxide (NO)
[69]. The net result being that the relative ability of CO to
induce cGMP production is significantly lower than that of
NO [70]. This led to the notion that guanylate cyclase is a
physiologic target of NO, but probably not of CO, despite
experimental evidence suggesting that CO can exert
biologic effects via cGMP (reviewed in [71]). Whether the
guanylate cyclase/cGMP pathway is involved in the
protective effect of CO against severe malaria remains to
be established.
CO can bind a variety of other hemoproteins, including
cytochrome C oxidase, the terminal electron acceptor in the
mitochondrial electron transport chain [72]. As for guanylate
cyclase, cytochrome C oxidase is also a physiologic target
of NO (reviewed in [73]). Binding of CO to cytochrome C
oxidase can trigger a small burst of mitochondria-derived
ROS [74–76] that activates several signal transduction
pathways. Among these is the p38 family of mitogen-
activated protein kinases (MAPK) [74, 75], a common
molecular denominator via which the anti-inflammatory
[61], cytoprotective [65], and anti-proliferative effects [62]
of CO are exerted in several cell types.
The p38 family of MAPK is composed of four isoforms
encoded by different genes, i.e., P38α (38 kDa), P38β
(39 kDa), P38γ (43 kDa), and P38δ (40 kDa; reviewed in
[77]). These share sequence homologies ranging from 74%
(P38α versus P38β) to 98% (P38β versus P38β2) and a
canonical dual phosphorylation site (Thr–Gly–Tyr; reviewed
in [77]). The kinase activity of the p38α and p38β isoforms
can be inhibited by pyridinyl imidazoles, a class of chemical
compounds that does not target the p38γ or p38δ isoforms.
The observation that pyridinyl imidazoles can abrogate
the anti-inflammatory [61], cytoprotective [65], and anti-
proliferative [62] effects of CO led to the hypothesis that
these effects might act via the p38α and/or the p38β
isoforms. In keeping with this notion, suppression of p38β
expression impairs the cytoprotective [65, 78, 79] and anti-
proliferative [80] effects of CO, suggesting that CO acts
specifically via this p38 MAPK isoform. Moreover, we
found that the mechanism via which CO signals via p38β
also involves the specific targeting of the p38α isoform for
degradation by the 26S proteasome pathway [78]. Presum-
ably, CO alters the ratio of p38α versus p38β expression,
allowing signaling via the cytoprotective p38β to predom-
inate over that of cytotoxic p38α [78]. Whether (1)
mitochondria-derived ROS, (2) p38α degradation, and/or
(3) signaling via p38β contribute to the protective effect of
CO against severe malaria remains to be established.
There are probably many other signal transduction
pathways via which the protective effects of CO can be
exerted (reviewed in [71]). Exposure of naïve Mø to CO in
vitro can induce the expression of peroxisome proliferator-
activated receptor-gamma (PPARγ) [75], a nuclear
hormone receptor that down-regulates a subset of pro-
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inflammatory genes associated with Mø activation [81].
Blocking mitochondria-driven ROS and/or deleting the
expression of PPARγ abrogates the anti-inflammatory
effects of CO, suggesting that this effect acts via up-
regulation of PPARγ, presumably via mitochondria-driven
ROS [75]. Yet, another signal transduction pathway
triggered by CO in Mø involves the transcription factor
hypoxia-inducible factor 1 alpha (HIF-1α) [76]. Activation
and stabilization of HIF1α by ROS arising from mito-
chondria induces the transcription of TGF-β [76], a potent
anti-inflammatory and cytoprotective cytokine that could
contribute to the salutary effects of CO in many inflam-
matory conditions, including in severe malaria. Again, the
contribution of these signal transduction pathways in the
control of the pathogenesis of severe malaria is not
defined.
In most studies addressing the mechanisms of action of
CO, the assumption has been that this gas targets one or
several “upstream” signal transduction pathways that
modulate the activity of transcription factors regulating
gene expression. However, there are instances where CO
can target transcription factors directly. This is the case for
the neuronal Per-ARNT-Sim (PAS) domain protein 2
(NPAS2), a transcription factor implicated in the regulation
of circadian rhythms [82]. Binding of CO to the heme
prosthetic group of NPAS2 controls NPAS2 heterodimeri-
zation with the brain and muscle arnt-like protein-1
(BMAL1), a transcription factor that regulates NPAS2
DNA binding and transcriptional activity [82]. Whether
NPAS2 regulates Plasmodium interaction with its human
host remains to be established, but is likely to be the case.
Cycles of RBC schizont infection (hemolysis, invasion,
replication) are highly synchronous [83] and therefore
could be controlled by host transcription factors that
regulate circadian rhythms, such as NPAS2.
Most, if not all, of the biological functions attributed to
CO are thought to rely on its binding to Fe2+ in the heme
prosthetic groups, e.g., guanylate cyclase, cytochrome C
oxidase, NAD(P)H oxidase (reviewed in [71]). The
postulate has been that CO can alter the 3D structure of
these hemoproteins and modulate in this manner their
biologic activity, i.e., signal transduction (reviewed in [71]).
While this notion has provided a useful framework to
explain the protective effects of CO, our recent finding of
an alternative mechanism via which CO can suppress the
onset of severe malaria might challenge this view.
Mechanism underlying the protective effects of CO:
inhibition of heme release from Hb
We found that one of the mechanisms via which CO
prevents the onset of cerebral malaria relies on its ability to
bind cell-free Hb and form carboxyHb (COHb; Fig. 3).
When bound to cell-free Hb, CO slows down its rate of
oxidation and, subsequently, the rate of heme release from
Hb [8] (Fig. 3). The critical involvement of free heme in the
pathogenesis of cerebral malaria is supported by the
following set of observations: (1) the protective effect of
CO is associated with a profound decrease (~95%) in the
accumulation of free heme in plasma of Plasmodium-
infected mice and (2) administration of heme precipitates
the onset of cerebral malaria, abrogating the protective
effect of CO [8].
There is further evidence that free heme can dictate
susceptibility to cerebral malaria in mice. We found that a
given Plasmodium strain that triggers cerebral malaria in
mice also leads to higher levels of free heme accumulation
in plasma, as compared to another related Plasmodium
strain that does not trigger cerebral malaria (Fig. 4a). More-
over, administration of free heme is sufficient per se to
precipitate the onset of cerebral malaria in mice infected with
the Plasmodium strain that does not trigger cerebral malaria
naturally (Fig. 4b). In a similar manner, a Plasmodium-
infected mouse strain that does not develop cerebral malaria
naturally (is resistant) has lower levels of plasma free heme,
as compared to a mouse strain that develops cerebral
malaria naturally (is susceptible; Fig. 4c). Again, heme
administration is sufficient per se to precipitate the onset of
cerebral malaria in the naturally resistant mouse strain
(Fig. 4d) [8]. Taken together, these observations suggest
that accumulation of free heme in plasma can explain at
least to some extent why some Plasmodium strains trigger
cerebral malaria while others do not, as well as why some
mouse strains are resistant to cerebral malaria while others
are susceptible.
While free heme seems to be critically involved in the
pathogenesis of cerebral malaria in mice, there is yet no
direct evidence linking functionally free heme to the
pathogenesis of severe and/or cerebral malaria in humans.
There is indirect evidence, however, to suggest that this
might be the case. Individuals developing severe malaria
have high levels of plasma metHb [41, 42]. As metHb
releases free heme, the prediction is that free heme should
accumulate in the plasma of these individuals, a hypothesis
we are currently testing. Moreover, individuals that suc-
cumb to cerebral malaria express high levels of HO-1 in the
brain [52, 53] and present high levels of plasma COHb, a
“biological fingerprint” of CO production by the HO
system [84]. Taken together, these observations suggest
that some of the key components involved in the
pathogenesis of severe malaria in mice, i.e., metHb, HO-1
and CO are also present during the pathogenesis of severe
malaria in humans. Whether the heme/HO-1 system should
also play a pivotal role in determining the onset of severe
malaria in humans remains to be established.
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Fig. 4 Free heme dictates the
onset of cerebral malaria in
mice. C57BL/6 or BALB/c mice
were inoculated (i.p.) with P.
berghei ANKA or P. berghei
NK65-infected RBC (105), i.e.,
infection [8]. a Survival and
heme concentration in protein-
free plasma of C57BL/6 mice
infected with either P. berghei
ANKA (black circles) or NK65
(white circles) at days 0 (n=7), 4
(n=4 for P. berghei ANKA), 6
(n=30 and n=16 for P. berghei
ANKA and NK65, respectively),
10 (n=10), and 15 (n=10) as it
relates to day of infection, i.e.,
day 0. Results are shown as
mean±standard deviation.
(*unpaired t test between P.
berghei ANKA and P. berghei
NK65-infected mice at day 6
post-infection, p<0.01). b Sur-
vival of C57BL/6 mice infected
with either P. berghei ANKA or
P. berghei NK65 receiving ve-
hicle (white circles; n=10),
60 μmol/kg (n=5; gray circles)
or 90 μmol/kg (n=12; black
circle) of free heme (i.p.; start-
ing at day 6 post-infection and
every 12 h thereafter). c Surviv-
al and heme concentration in
protein-free plasma of C57BL/6
mice (black circle) or BALB/c
mice (white circle) infected with
P. berghei ANKA at days 0 (n=
7 and n=6 for P. berghei
ANKA-infected C57BL/6 mice
and BALB/c mice, respective-
ly), 4 (n=4 for P. berghei
ANKA-infected C57BL/6 mice),
6 (n=30 and
n=15, for P. berghei ANKA-
infected C57BL/6 mice and
BALB/c mice, respectively), 10
(n=10) and 15 (n=12) as it
relates to day of infection, i.e.,
day 0. Results are shown as
mean±standard deviation
(*unpaired t test between P.
berghei ANKA-infected C57BL/
6 and BALB/C mice at day 6
post-infection, p<0.01). d Sur-
vival of P. berghei ANKA-
infected BALB/c mice receiving
vehicle (white circle; n=10),
60 μmol/kg (n=9; grey circles),
or 90 μmol/kg (n=6; black
circle) free heme (i.p; starting at
day 6 post-infection and every
12 h thereafter)
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Effector mechanism(s) via which free heme triggers
the onset of cerebral malaria
The mechanism(s) via which free heme precipitates the
pathogenesis of severe malaria, and in particular that of
cerebral malaria, are not fully elucidated. Cerebral malaria
is associated with the development of BBB disruption and
brain edema in both mice [8] and humans [85] (reviewed in
[5]). However, the molecular mechanism(s) leading to BBB
disruption are not fully understood. Postmortem studies in
humans diagnosed with cerebral malaria suggest that BBB
leakage is associated with adhesion of infected RBCs to
brain microvascular endothelial cells, a phenomenon
referred to as RBC sequestration (reviewed in [3, 4]). A
functional link between these two events, i.e., BBB leakage
and RBC sequestration, is supported by a series of
observations suggesting that adhesion of infected RBCs to
endothelial cells in vitro can induce the disruption of tight
junctions, a multiprotein structure that maintains BBB
integrity (reviewed in [3, 4]). However, there are probably
additional mechanisms that can operate, independently of
RBC sequestration, to trigger BBB disruption.
Using an in vitro assay in which brain endothelial cells
form tight junctions, free heme was found to promote the
disruption tight junction function [8]. This effect requires
the presence of ROS, which would explain why free heme
triggers BBB disruption only in Plasmodium-infected but
not in naïve mice [8]. This observation also suggests that
CO suppresses BBB disruption by preventing the accumu-
lation of free heme in the brain microvasculature [8]. Given
the above, we propose that CO might be used to suppress
the onset of cerebral malaria for as long as plasma free
heme concentration is kept below a certain threshold level
at which BBB disruption occurs and CO would lose its
protective effect [8]. Whether a similar therapeutic effect
would be attained in children diagnosed as having or at risk
of developing cerebral malaria remains to be established.
Finally, and assuming that free heme is involved in the
pathogenesis of severe and/or cerebral malaria in humans,
one could consider measuring plasma free heme concen-
tration to diagnose this pathologic condition.
There are several unsolved issues raised by these
findings including the identification of the sources of
ROS that oxidize cell-free Hb, leading to the generation
of free heme and to the onset of cerebral malaria. Based on
the observation that NAD(P)H gp91phox-deficient mice can
develop cerebral malaria, it has been suggested that ROS
are probably not involved in its pathogenesis [86]. Our
interpretation is somehow different. We propose that while
ROS are most probably involved in the pathogenesis of
cerebral malaria, gp91phox is probably not the main source
of ROS leading to the onset of this disease. By extending
this line of thought, one could consider many other putative
sources of superoxide generating systems. These include
the gp91phox homologue Nox genes, e.g., Nox4 and Nox1,
both of which are major components of vascular NAD(P)H
oxidase-like complexes operating in the brain microvascu-
lature. In addition, the brain vasculature also expresses
relatively high levels of xanthine oxidase and cyclooxyge-
nase-1, both of which are potent superoxide anion
producers. Another possibility is that the reducing potential
of the brain microvasculature might be altered during
Plasmodium infection in a way that would promote the
accumulation of ROS. This could be a direct consequence
of decreased expression of antioxidant genes, e.g., FtH,
superoxide dismutase, catalase, or glutathione peroxidase.
While the participation of these host genes in the
pathogenesis of severe malaria and/or cerebral malaria
remains to be tested, it becomes apparent that many
possible sources of ROS or their regulators may be
involved in its pathogenesis (Fig. 5).
Fig. 5 CO prevents the onset of cerebral malaria via inhibition of
heme release from cell-free Hb. When exposed to ROS generated in
the brain vasculature by enzymes such as NAD(P)H oxidase, xanthine
oxidase, cyclooxygenase, lipoxygenases, and/or riboflavin, dimeric
cell-free ferrous HbFe2+ (αβ) is oxidized into ferric HbFe3+ (αβ), i.e.,
metHb (not shown), which releases heme promptly. Accumulation of
free heme in plasma of Plasmodium-infected mice allows the Fe
contained within the protoporhyrin IX ring of heme to participate in
further generation of ROS via the Fenton chemistry. ROS synergize
with activated CD8+ T cells to trigger the development of cerebral
malaria. When the expression of HO-1 is induced, free heme
availability is reduced via two pathways: (1) heme degradation and
(2) generation of CO, which binds dimeric cell-free ferrous HbFe2+
(αβ) and suppresses further heme release from Hb. The combined
effect of HO-1 and its end product CO suppresses the onset of cerebral
malaria in mice [8]
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Integrating the heme/HO-1/CO system with other
mechanisms contributing to the pathogenesis of cerebral
malaria
Unfettered expression of pro-inflammatory genes is most
probably a central component in the pathogenesis of severe
malaria and/or cerebral malaria [87]. Given the above, the
anti-inflammatory effects of CO should contribute to
prevent the onset of these pathologic conditions [8, 61]
(reviewed in [66]). In support of this notion, CO reduces
the expression of key pro-inflammatory genes involved in
the pathogenesis of cerebral malaria in mice, e.g., ICAM-1/
CD54, vascular cell adhesion molecule-1 (VCAM-1/
CD106), TNF, LT, and interferon-gamma (IFN-γ) [8].
As discussed under “Deleterious effects of free heme”,
recognition of Plasmodium-derived PAMP by host PRR
might be involved in the pathogenesis of severe malaria in
humans [10]. When bound to the heme prosthetic group of
the gp91phox subunit of the superoxide anion-generating
enzyme NAD(P)H oxidase, CO inhibits ROS production in
Mø [88], thus effect inhibits TLR2, 4, 5, and 9 signaling
[88]. It is possible therefore that inhibition of NAD(P)H
oxidase by CO or other gp91phox-like superoxide-generat-
ing enzymes should contribute to prevent the involvement
of these PRR in the onset of severe malaria.
While immunocompetent mice require the expression of
HO-1 to prevent the onset of cerebral malaria, this is no
longer the case when mice lack T and B cells, i.e., severe
combined immunodeficiency or when CD8+ T cells are
depleted from immunocompetent mice [8]. This would
suggest that HO-1 down-modulates the activation or
effector function of CD8+ T cells and/or that it acts in the
brain microvasculature to prevent the cytotoxic effects of
CD8+ T cells. The observation that pharmacologic induc-
tion of HO-1 or exposure to CO results in a profound
inhibition of CD8+ T cell sequestration in the brain of
Plasmodium-infected mice [8] suggests that CO suppresses
CD8+ T cells activation and/or effector function. As free
heme can act as a potent T cell mitogen [89, 90], it is
possible that inhibition of heme release from cell-free Hb
would also down modulate the activation and/or effector
function of CD8+ T cells.
There is yet another mechanism via which CO might
exert protective effects that could prevent the pathogenesis
of cerebral malaria. Plasmodium infection is associated
with a profound reduction of NO bioavailability both in
mice [9] and in humans [91], an effect that precipitates the
onset of cerebral malaria in mice [9]. Reduction of NO
bioavailability occurs via several pathways, including the
release of arginase by infected RBCs, an enzyme that
degrades the rate-limiting substrate for NO synthesis, i.e.,
arginine (reviewed in [23]). In addition, cell-free Hb also
acts as a potent NO scavenger, an effect that reduces NO
bioavailability [9, 92]. It has been recently shown that in a
similar way to CO, NO inhalation or administration of
pharmacologic compounds that release NO suppresses the
onset of severe malaria in mice [9]. As NO and CO target
the same heme prosthetic groups in cell-free Hb, it is
possible that these two gases may interact functionally. For
example, it is conceivable that once bound to cell-free Hb,
CO could reduce its NO scavenging capacity, thus
increasing NO bioavailability and suppressing in this
manner the onset of cerebral malaria [9]. This might occur
even if CO binds to the heme groups of cell-free Hb with an
affinity that is ~1,500 lower to that of NO, as contrary to
CO, NO is very labile, reacting avidly with ROS to
generate peroxynitrite. This hypothesis is currently being
tested in our laboratory.
Concluding remarks
The data we have obtained in rodent models of malaria
suggest that survival of a Plasmodium-infected host is
strictly dependent on its ability to induce the expression of
the heme-catalyzing enzyme HO-1. CO, an end product of
heme catabolism by HO-1, supresses the development
of severe malaria, i.e., cerebral malaria. The protective
effect of CO is mediated not only via its cytoprotective and
anti-inflammatory effects but also via inhibition of heme
release from cell-free Hb generated during the blood stage
of Plasmodium infection. One of the key notions that arise
from these findings is that at least in mice, free heme seems
to play a critical role in the pathogenesis of cerebral
malaria. If this also proves to be the case in humans, then
one might be able to use plasma free heme concentration to
diagnose the onset of severe and/or cerebral malaria and
eventually use therapeutic approaches that target free heme,
including CO administration, to overcome the onset of
these pathologic conditions.
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